<DOC>
	<DOCNO>NCT01128114</DOCNO>
	<brief_summary>The primary objective study evaluate broad clinical benefit dose Seroquel XR flexible treatment acute bipolar mania patient partial response exist therapy . Clinical benefit assess Clinical Global Impression-Clinical Benefit ( CGI-CB ) score , accord classification base principle outline CGI efficacy index . Improvement clinical benefit define decrease baseline CGI-CB .</brief_summary>
	<brief_title>Study Broad Clinical Benefit Seroquel XR With Flexible Dose add-on Therapy Treatment Acute Bipolar Mania Patients With Partial Response Current Therapy</brief_title>
	<detailed_description>A 4-week , Multi-Centre , Open-label , Non-comparative , Phase IV Study Broad Clinical Benefit Seroquel XR ( Quetiapine Fumarate Extended Release ) With Flexible Dose add-on Therapy Treatment Acute Bipolar Mania Patients With Partial Response Current Therapy</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Documented clinical diagnosis meeting Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion ( 1 . Bipolar I Disorder , manic mixed type with/without psychotic feature , 2 . Diagnosis confirm Mini Inte ) Currently Lithium/Valproate without antipsychotic 3 week consecutive treatment YMRS total score â‰¥16 study entry Nonresponse antipsychotic treatment manic symptom previous episodes A patient Diabetes Mellitus ( DM ) fulfil one follow criterion ( 1 . Unstable DM define enrolment glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % , 2 . Admitted hospital treatment DM DM relate illness past 12 week , etc ) An absolute neutrophil count ( ANC ) 1.5 x 10^9 per liter</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acute bipolar mania</keyword>
	<keyword>Seroquel XR</keyword>
	<keyword>Quetiapine fumarate</keyword>
	<keyword>Add-on therapy</keyword>
</DOC>